QBIO - Q BioMed Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
2.46
+0.16 (+6.96%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close2.30
Open2.34
Bid0.00 x 0
Ask0.00 x 0
Day's Range2.33 - 2.49
52 Week Range1.67 - 5.90
Volume45,758
Avg. Volume76,479
Market Cap35.031M
Beta (3Y Monthly)1.58
PE Ratio (TTM)N/A
EPS (TTM)-1.00
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.38
Trade prices are not sourced from all markets
  • PR Newswire12 days ago

    Q BioMed Provides Important Update on QBM001 Developmental Drug Targeting a Non-Verbal and Minimally Verbal Patient Subset on the Autism Spectrum

    Q BioMed Inc. (QBIO), a biotechnology acceleration company, is pleased to provide an update on QBM001, its Autistic Spectrum Disorder (ASD) drug development program for non-verbal or minimally verbal autistic children. Q BioMed continues to develop its intellectual property including its patent pending QBM-001 drug technology, which is being tested for pediatric developmental nonverbal disorder in toddlers within the autism spectrum disorders.

  • PR Newswire27 days ago

    Q Biomed Inc. Announces Entry Into Definitive Funding Agreement for $4,000,000

    Q BioMed Inc. (QBIO), is pleased to announce that it has entered into a definitive agreement with Yorkville Advisors Global ('Yorkville') for $4,000,000. Q BioMed has closed on the initial tranche of $2,000,000 and expects to close on the balance pending the filing of a registration statement with the U.S. Securities and Exchange Commission for the underlying shares. Q BioMed Inc. CEO, Denis Corin said, "We are very pleased to once again partner with Yorkville as we enter a very milestone intensive period for Q BioMed.

  • Q Biomed Inc. Announces Dr. Rajendra Apte Joins Advisory Board
    PR Newswirelast month

    Q Biomed Inc. Announces Dr. Rajendra Apte Joins Advisory Board

    Distinguished Ophthalmology Specialist Brings Wealth of Experience NEW YORK , Sept. 17, 2018 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotechnology acceleration development company, ...

  • PR Newswire2 months ago

    Q BioMed Inc. Announces FDA Filing for Strontium Chloride Sr89 Injection USP for Relief of Metastatic Cancer Bone Pain

    NEW YORK, Aug. 20, 2018 /PRNewswire/ -- Q BioMed Inc. (QBIO) (QBIO), a commercial stage biotechnology acceleration development company, and BioNucleonics, licensor of Strontium 89 Chloride, announce submission of a supplemental regulatory filing to the FDA for the approval of a new manufacturing facility. Once cleared by the FDA, the facility will be permitted to manufacture Strontium Chloride Sr89 Injection USP in accordance with cGMP. Strontium Chloride Sr89 Injection USP is an FDA-approved non-opioid injectable radiopharmaceutical indicated to relieve cancer bone pain in patients with painful skeletal metastases.

  • PR Newswire3 months ago

    Q Biomed Inc. Extends its Exclusive Option Agreement With Washington University in St. Louis for a Novel Companion Biomarker for Monitoring Glaucoma and Initiates a Clinical Study

    Q BioMed Inc. (QBIO), a commercial stage biotechnology acceleration development company, is pleased to announce that it is extending its option agreement with Washington University in St. Louis. Under the agreement granting the exclusive right to license the technology, Q BioMed will continue to evaluate the feasibility and usability of GDF15, a novel biomarker for monitoring glaucoma, as a companion diagnostic to the MAN-01 small molecule currently being optimized for the topical treatment of glaucoma. The extension allows for more extensive evaluation to be conducted on the feasibility and usability of GDF15 as a novel biomarker for glaucoma and companion diagnostic to, Q BioMed's exclusively licensed technology, MAN-01.

  • PR Newswire5 months ago

    Q BioMed Inc. Provides Important Update on Mannin Research Tie2 Technology Platform Development

    Q BioMed Inc. (QBIO), a commercial stage biotechnology acceleration development company, provides the following update on its exclusively licensed platform technology asset from Mannin Research Inc. Together with Mannin Research, the company has made significant progress on their Tie2 activating molecule - currently being optimized for a topical eye drop for the treatment of open angle glaucoma. This is a tremendous achievement and involved significant and detailed work, giving them broad coverage of the platform from an intellectual property standpoint.

  • PR Newswire5 months ago

    Q BioMed Inc Places 2nd in Company Category for Autism Speaks Walk Fundraiser

    Q BioMed Inc. (QBIO), a biotechnology acceleration company, placed second in the 'company category' at this year's Bay Area Autism Speaks Walk. The fundraiser provided Q BioMed an opportunity to connect with and better understand the autism spectrum disorder (ASD) community as the company progresses with QBM-001, which is being developed to treat pediatric developmental nonverbal disorder in toddlers with ASDs. "We gave it an all-out team effort to support the autism community, and we are happy to support Autism Speaks' efforts to raise awareness and educate, fund research, and support patients and caregivers," explained Denis Corin, CEO of Q BioMed.

  • PR Newswire7 months ago

    Q Biomed Inc. to Present at the Microcap Conference Taking Place April 9-10 at the Essex House in New York City

    NEW YORK , April 5, 2018 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotechnology acceleration company, announced today that Denis Corin , Chief Executive Officer, will present at ...

  • PR Newswire7 months ago

    Q Biomed Inc. Announces FDA Filing for Approval of a New Manufacturing Facility for Non-Opioid Strontium Chloride SR89 Injection USP for Relief of Cancer Bone Pain

    Q BioMed Inc. (QBIO), a commercial stage biotechnology acceleration development company, and Bio-Nucleonics, licensor of Strontium 89 Chloride, announce submission of a regulatory filing to the FDA for the approval of a new manufacturing facility. Upon approval by the FDA, the facility will be permitted to manufacture Strontium Chloride Sr89 Injection USP (Strontium-89) in accordance with cGMP. Strontium-89 is a non-opioid injectable radiopharmaceutical to relieve cancer bone pain in patients with painful skeletal metastases.

  • PR Newswire7 months ago

    Q BioMed Inc. to Present at 30th Annual Roth Conference, Taking Place March 11-14, 2018, in Dana Point, CA

    NEW YORK , March 9, 2018 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotechnology acceleration company, announced today that Denis Corin , Chief Executive Officer will present at the ...

  • OTCQX And OTCQB Companies to Present At 2018 ROTH Conference
    PR Newswire7 months ago

    OTCQX And OTCQB Companies to Present At 2018 ROTH Conference

    OTC Markets Group EVP Jason Paltrowitz to Speak on Panel on "Reg A+ Offerings" NEW YORK , March 8, 2018 /PRNewswire/ -- OTC Markets Group Inc.  (OTCQX: OTCM), operator of financial markets for ...

  • ACCESSWIRE8 months ago

    The Story Behind Growth: New Report Discusses CytoDyn Inc. and Q Biomed Inc. - Emerging Trends Within New Industry

    NEW YORK, NY / ACCESSWIRE / February 2 2 , 2018 / Latest key findings by Growth Market Report for all traders, shareholders, and investors of CytoDyn Inc. (OTCQB: CYDY ) and Q Biomed Inc. (OTCQB: QBIO ...

  • PR Newswire8 months ago

    Q BioMed Adds Big Pharma Executive to Board of Directors

    Q BioMed Inc. (QBIO), a biotechnology acceleration company, is pleased to welcome Dr. Rick Panicucci as an independent member on its board of Directors. Dr. Rick Panicucci is the Vice President of Pharmaceutical Development at STA Pharmaceutical Co. Ltd. (A WuXi AppTec Company). Rick has been providing formulation and development support to Mannin Research on Man01, our glaucoma drug candidate.

  • PR Newswire8 months ago

    Q Biomed Inc. Signs Exclusive Option Agreement With Washington University in St. Louis for a Novel Companion Biomarker for Monitoring Glaucoma

    Q BioMed Inc. (QBIO), is pleased to announce an exclusive option agreement with Washington University in St. Louis. Under the agreement granting the exclusive right to license the technology, Q BioMed will evaluate the feasibility and usability of GDF-15, a novel biomarker for monitoring glaucoma, as a companion diagnostic to the MAN-01 small molecule currently being optimized for the topical treatment of glaucoma.

  • PR Newswire9 months ago

    Q Biomed Inc. Closes $5.48 Million Public Offering

    Q BioMed Inc. (QBIO), a commercial stage biotechnology acceleration development company, is pleased to announce the closing of its previously announced public offering of an aggregate of 1,711,875 units consisting of one common and share and one warrant at a public offering price of $3.20 per unit for gross proceeds of $5.48 million. Roth Capital Partners acted as lead placement agent and CIM Securities acted as co-lead placement agent for the offering.

  • PR Newswire9 months ago

    Q BioMed Inc. Prices $5.5 Million Public Offering

    Q BioMed Inc. (QBIO) ("Q BioMed" or the "Company"), a commercial stage biotechnology acceleration development company is pleased to announce pricing of a public offering of an aggregate of 1,711,875 shares of common stock of the Company, together with warrants to purchase up to 1,711,875 shares of common stock of the Company, at a public offering price of $3.20 per share and associated warrant. The gross proceeds from the offering are expected to be approximately $5.5 million, before deducting placement agent fees and other estimated offering expenses. Roth Capital Partners is acting as lead placement agent and CIM Securities is acting as co-lead placement agent for the offering.

  • PR Newswire10 months ago

    Q Biomed Inc. to Present at Biotech Showcase(™) 2018

    NEW YORK , January 3, 2018 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration company announced today that Denis Corin , Chief Executive Officer, will present at the Biotech Showcase(™) ...

  • PR Newswire10 months ago

    Q BioMed Provides Year End Update

    NEW YORK, Dec. 21, 2017 /PRNewswire/ -- Q BioMed Inc. (QBIO), a biotechnology acceleration company, is pleased to provide this year end update to its shareholders. The Company also ends the year with a clean balance sheet, having settled all outstanding debt and is poised for a very productive a catalyst-rich year in 2018. Strontium-89 is a U.S. Food and Drug Administration approved drug for pain palliation in bone metastases, primarily from breast, prostate and lung cancers.

  • PR Newswire11 months ago

    Q BioMed Announces Full Settlement of All Convertible Debt

    Q BioMed Inc. (QBIO), a biotechnology acceleration Company, announced today that all convertible notes and loans have been settled in full, including the $4 million of convertible notes that had been issued pursuant to a Securities Purchase Agreement dated November 29, 2016. The company ended its 2017 financial year with no outstanding loans or convertible debt. This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.

  • PR Newswire11 months ago

    Q BioMed Adds Boston University's Dr. Tager-Flusberg to Advisory Committee

    Q BioMed Inc. (QBIO), a biotechnology acceleration company, announced today that Dr. Helen Tager-Flusberg from Boston University has joined its advisory committee for QBM-001, which is being tested for pediatric developmental nonverbal disorder in toddlers within the autism spectrum disorders. Dr. Tager-Flusberg has provided the protocol for capturing the primary endpoint of the planned trial for QBM-001.

  • PR Newswire11 months ago

    Q Biomed Inc. Announces Funding to Technology Partner Mannin Research Inc. to Expand Product Pipeline

    Q BioMed Inc. (QBIO) congratulates our collaborative research partner and licensor, Mannin Research Inc., on receiving R&D funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to initiate work on a Tie2-activating biologic for the treatment of glaucoma. Q BioMed has licensed the Mannin Tie2 technology, and is collaboratively developing the Tie2 platform for glaucoma, and other indications. This new biologic would be an additional product to the Mannin Tie2 pipeline.